Immunocore Holdings (IMCR) Revenue (2021 - 2026)
Immunocore Holdings (IMCR) posted Revenue of $106.7 million for Q1 2026, up 2.1% sequentially from $104.5 million in Q4 2025, and up 13.63% YoY from $93.9 million in Q1 2025.
Immunocore Holdings (IMCR) Revenue (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Revenue for 6 years, with the latest figure at $106.7 million in Q1 2026.
- Quarterly Revenue rose 13.63% year-over-year to $106.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $412.8 million (up 23.75% YoY) and the FY2025 annual result came in at $400.0 million, up 28.95% from the prior year.
- Revenue grew to $106.7 million in Q1 2026 per IMCR's latest filing, from $104.5 million in the prior quarter.
- Over five years, Revenue peaked at $106.7 million in Q1 2026 and troughed at $40.3 million in Q2 2022.
- A 5-year average of $75.7 million and a median of $73.0 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2026: Revenue surged 534.3% in 2022, then advanced 13.63% in 2026.
- Over 5 years, Revenue stood at $56.4 million in 2022, then advanced by 24.46% to $70.2 million in 2023, then advanced by 19.8% to $84.1 million in 2024, then grew by 24.3% to $104.5 million in 2025, then climbed by 2.1% to $106.7 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $106.7 million, $104.5 million, and $103.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Immunocore Holdings | 1.76 Bn | 880.92 Mn | 114.84 Mn | 115.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.93 Mn |
| Mar 31, 2026 | 106.68 Mn |
| Dec 31, 2025 | 104.48 Mn |
| Sep 30, 2025 | 103.69 Mn |
| Jun 30, 2025 | 97.96 Mn |
| Mar 31, 2025 | 93.88 Mn |
| Dec 31, 2024 | 84.05 Mn |
| Sep 30, 2024 | 80.25 Mn |
| Jun 30, 2024 | 75.40 Mn |
| Mar 31, 2024 | 70.50 Mn |
| Dec 31, 2023 | 70.16 Mn |
| Sep 30, 2023 | 64.85 Mn |
| Jun 30, 2023 | 59.76 Mn |
| Mar 31, 2023 | 54.66 Mn |
| Dec 31, 2022 | 56.37 Mn |
| Sep 30, 2022 | 48.56 Mn |
| Jun 30, 2022 | 40.30 Mn |
| Dec 31, 2021 | 8.89 Mn |
| Sep 30, 2021 | 8.17 Mn |